Table 3

Motor toxicity (TD50), anticonvulsant potency (ED50) against PTZ-induced seizures and protective indices (PI) of DZP alone and in combination with the neurosteroids and PB

TreatmentTD50TD50 (DZP + Vehicle)ED50ED50 (DZP + Vehicle)PI
TD50 (combination)ED50(combination)
DZP + vehicle3.1310.26112.0
(1.88–5.23)(0.15–0.45)
DZP + 3α,5α-P (1.7)2.051.50.0353-a 7.458.6
(1.31–3.23)(0.0013–0.091)
DZP + 3α,5β-P (3)1.502.10.00673-a 38.8224
(0.80–2.80)(0.0012–0.038)
DZP + Ganaxolone (3)1.731.80.00533-a 49.1326
(0.91–3.29)(0.0012–0.023)
DZP + Co 2-1068 (3)2.511.20.00703-a 37.1359
(1.06–5.95)(0.0010–0.048)
DZP + PB (3)2.881.10.00973-a 26.8297
(2.16–3.85)(0.0033–0.029)
  • The data represent the TD50 and ED50 values (in mg/kg with 95% confidence limits in parentheses) evaluated in DZP alone (DZP + vehicle) and DZP + drug-treated groups. Ratios of respective TD50 (DZP + vehicle)/TD50(combination) and ED50 (DZP + vehicle)/ED50(combination) as well as protective indices (PI = TD50/ED50) were calculated for combined treatments. The adjuvants were administered at their maximal ineffective doses against PTZ, as listed in parentheses (in mg/kg) next to respective names. TD50 values for combined treatments did not differ from that for (DZP + vehicle)-treated group.

  • 3-a P < .05; compared to ED50 of (DZP + vehicle)-treated group (Litchfield and Wilcoxon, 1949).